AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 24059911
Drug: Alternative artemisinin-based
RxNorm normalized name: artemisinin
DrugBank: Artemisinin (DB13132)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alternative artemisinin-based combination therapy
Trial: 24059911
Drug: Same first-line
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Same first-line artemisinin-based combination therapy
Trial: 20801439
Drug: GnRH agonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH agonist inducing a hypogonadic state during IVF-ET cycles
Trial: 19694927
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg Udenafil
Trial: 19694927
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg Udenafil
Trial: 17426277
Drug: 75 microg
RxNorm normalized name: Norgestrel 75 microgram oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 microg rHA0 vaccine (15 microg H1, 45 microg H3)
Trial: 17426277
Drug: 135 microg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 135 microg rHA0 vaccine (45 microg each of H1, H3, B)
Trial: 8886414
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg TAK-044
Trial: 8886414
Drug: 750 mg
RxNorm normalized name: bran 750 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 750 mg TAK-044
Trial: 26137496
Drug: Mindful awareness
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mindful awareness practices (MAP), 8 weekly sessions
Trial: 12407127
Drug: Linezolid 600
RxNorm normalized name: linezolid 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Linezolid 600 mg twice a day for 7 days
Trial: 12407127
Drug: Co-amoxiclav 1000
RxNorm normalized name: CO
DrugBank: Carbon monoxide (DB11588)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co-amoxiclav 1000 mg once a day for 7 days
Trial: 8711052
Drug: Group Rational-Emotive
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group Rational-Emotive Behavior Therapy (9 weekly sessions)
Trial: 8711052
Drug: Delayed treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed treatment control group (no intervention during control period)
Trial: 1748109
Drug: Branched-chain amino
RxNorm normalized name: Branched-chain amino acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Branched-chain amino acids (BCAA) supplement during the race
Trial: 1748109
Drug: Branched-chain amino
RxNorm normalized name: Branched-chain amino acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Branched-chain amino acids (BCAA) supplement during the marathon
Trial: 2858709
Drug: Tamoxifen 10
RxNorm normalized name: tamoxifen 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen 10 mg twice daily for two years
Trial: 27333088
Drug: Maraviroc (MVC)
RxNorm normalized name: Maraviroc
DrugBank: Maraviroc (DB04835)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Maraviroc (MVC) 150 mg
Trial: 22332800
Drug: 15 mg/day
RxNorm normalized name: Climara Pro 0.045/0.015 MG/Day Weekly Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg/day MMI
Trial: 22332800
Drug: 30 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg/day MMI
Trial: 22332800
Drug: 300 mg/day
RxNorm normalized name: alpelisib 300 mg/day (150 mg x 2) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg/day PTU
Trial: 19787388
Drug: Limb remote
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Limb remote ischemic preconditioning (RIPC) induced twice (24 h and 1 h preoperatively) via three 5‐min cycles of ischemia and reperfusion on the left upper arm using a blood pressure cuff.
Trial: 17520260
Drug: Mud-bath treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mud-bath treatment (12 mud packs and thermal baths)
Trial: 17590368
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no mud-bath treatment)
Trial: 17956712
Drug: zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: zoledronic acid 4 mg
Trial: 9349604
Drug: Troglitazone 400
RxNorm normalized name: troglitazone 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Troglitazone 400 mg twice daily for 2 weeks
Trial: 1347231
Drug: Vecuronium 0.08
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vecuronium 0.08 mg kg‐1 or 0.10 mg kg‐1
Trial: 1347231
Drug: Atracurium 0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atracurium 0.4 mg kg‐1 or 0.5 mg kg‐1
Trial: 29472491
Drug: Monthly sulfadoxine‐pyrimethamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monthly sulfadoxine‐pyrimethamine and 2 doses of azithromycin (AZI‐SP)
Trial: 29472491
Drug: Control (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (2 doses of sulfadoxine‐pyrimethamine)
Trial: 29472491
Drug: Monthly sulfadoxine‐pyrimethamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monthly sulfadoxine‐pyrimethamine
Trial: 26899387
Drug: 0.5 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 μg calcitriol orally twice a day for 3 days prior to surgery
Trial: 26899387
Drug: Selective vitamin
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selective vitamin D treatment for patients with postoperative hypocalcaemia (control)
Trial: 9528716
Drug: Trovafloxacin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trovafloxacin (100 mg tablet)
Trial: 9528716
Drug: Ofloxacin (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ofloxacin (200 mg capsules, 2 capsules)
Trial: 7543060
Drug: G‐CSF (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G‐CSF (10 g/kg/day subcutaneously and daily)
Trial: 9605644
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no G‐CSF)
Trial: 2702989
Drug: Aminoglutethimide (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aminoglutethimide (2 x 125 mg, 3 x 125 mg, or 2 x 250 mg daily)
Trial: 27332770
Drug: Single induction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single induction chemotherapy regimen C (four cycles of vincristine, carboplatin, and temozolomide) followed by marrow-ablative chemotherapy and autologous hematopoietic cell rescue.
Trial: 25169040
Drug: Bolus infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bolus infusion of 2,000 μg sodium selenite immediately prior to surgery, followed by an additional dosage of 2,000 μg at ICU admission, and a further daily supplementation of 1,000 μg up to 10 days or ICU discharge
Trial: 25169040
Drug: Placebo administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administration at the same time points
Trial: 17391565
Drug: Extra-virgin olive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extra-virgin olive oil (EVOO) with 1125 mg polyphenols/kg and 350 mg tocopherols/kg
Trial: 12831586
Drug: Protocol II
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protocol II (gonadotrophins started during clomiphene citrate administration)
Trial: 6288396
Drug: Enprofylline 2
RxNorm normalized name: Enprofylline
DrugBank: Enprofylline (DB00824)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enprofylline 2 mg/kg
Trial: 6288396
Drug: Enprofylline 2
RxNorm normalized name: Enprofylline
DrugBank: Enprofylline (DB00824)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enprofylline 2 + 4 mg/kg
Trial: 6288396
Drug: Theophylline 9.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theophylline 9.2 +/- 0.9 mg/kg
Trial: 29265379
Drug: Naltrexone (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naltrexone (50 mg/d for 5 days)
Trial: 15786486
Drug: Olanzapine (average
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine (average dosage 12.3 mg/day)
Trial: 11882225
Drug: rocuronium 0.9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rocuronium 0.9 mg.kg‐1
Trial: 11882225
Drug: suxamethonium 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: suxamethonium 1.5 mg.kg‐1
Trial: 3069238
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment (Pharmalgen, D. pteronyssinus)
Trial: 22719796
Drug: Pharmacy surveillance
RxNorm normalized name: miconazole
DrugBank: Miconazole (DB01110)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Pharmacy surveillance using a web‐based surveillance tool to monitor drug prescribing and kidney function trends.
Trial: 16027572
Drug: Levalbuterol 1.25
RxNorm normalized name: levalbuterol 1.25 mg/3 mL inhalation solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levalbuterol 1.25 mg via nebulization
Trial: 16027572
Drug: Racemic albuterol
RxNorm normalized name: Albuterol
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Racemic albuterol 2.5 mg via nebulization
Trial: 8042234
Drug: Double-drug therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double-drug therapy (DT)
Trial: 8042234
Drug: Triple-drug therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple-drug therapy (TT)
Trial: 27862577
Drug: Ferumoxytol (FE)
DrugBank: Ferumoxytol (DB06215)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Ferumoxytol (FE) 4 mg/kg
Trial: 27862577
Drug: Ferumoxytol (FE)
DrugBank: Ferumoxytol (DB06215)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Ferumoxytol (FE) 2 mg/kg
Trial: 25471273
Drug: Sodium citrate
RxNorm normalized name: Sodium Citrate
DrugBank: Sodium nitrate (DB15952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium citrate (CIT) ingestion (500 mg kg(‐1) body mass)
Trial: 17136040
Drug: alpha (s1)‐casein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: alpha (s1)‐casein hydrolysate (150 mg/day for 30 days)
Trial: 22687786
Drug: rosuvastatin 40
RxNorm normalized name: rosuvastatin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rosuvastatin 40 mg/day
Trial: 9270561
Drug: cM-T412 antibody
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cM-T412 antibody infusion
Trial: 2885117
Drug: Nisoldipine 10
RxNorm normalized name: nisoldipine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nisoldipine 10 mg daily combined with beta-adrenergic-blocking drugs
Trial: 2885117
Drug: Beta-adrenergic-blocking drugs
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-adrenergic-blocking drugs alone (single therapy)
Trial: 21962943
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of oral misoprostol (OM) and mechanical dilation with a double‐balloon catheter
Trial: 21962943
Drug: Oral misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral misoprostol (OM) only
Trial: 21962943
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of oral misoprostol (OM) and mechanical dilation with a double‐balloon catheter (excluding cases with premature rupture of membranes)
Trial: 21962943
Drug: Oral misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral misoprostol (OM) only (excluding cases with premature rupture of membranes)
Trial: 10614032
Drug: 2.0 mg
RxNorm normalized name: LORAZEPAM 2.0 mg in 1 mL INTRAVENOUS INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.0 mg intravenous naloxone administered 2 minutes prior to ECT treatments
Trial: 26568032
Drug: Tosedostat (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tosedostat (120 mg on days 1-21 or 180 mg continuously) with cytarabine (1 g/m2/d) or decitabine (20 mg/m2/d) every 35 days
Trial: 19578230
Drug: Intravenous human
RxNorm normalized name: botulism immune globulin IV human Injection [BabyBIG]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous human albumin 20% (1 g/kg) one hour before exchange
Trial: 16078036
Drug: Helicobacter pylori
RxNorm normalized name: HELICOBACTER PYLORI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Helicobacter pylori (HP) eradication therapy
Trial: 16078036
Drug: Proton pump
RxNorm normalized name: Proton pump inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proton pump inhibitor (PPI) monotherapy
Trial: 10367046
Drug: Low-dose intermittent
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose intermittent MFP (3 months on, 1 month off) with 1000 mg calcium/day (average daily fluoride ion dose of 11.2 mg)
Trial: 10367046
Drug: Continuous MFP
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous MFP with 1000 mg calcium/day (20 mg fluoride ions per day)
Trial: 10367046
Drug: Calcium alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium alone (1000 mg/day)
Trial: 6780232
Drug: Intravenous nitroglycerin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous nitroglycerin (continuous infusion over 48 hours initiated within 8 hours after onset of symptoms)
Trial: 6780232
Drug: Intravenous nitroglycerin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous nitroglycerin (late intervention, therapy begun more than 8 hours after onset of symptoms)
Trial: 6780232
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no nitroglycerin treatment)
Trial: 31619359
Drug: Topical amphotericin
RxNorm normalized name: amphotericin
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical amphotericin 0.15% plus CXL
Trial: 31619359
Drug: CXL regardless
RxNorm normalized name: CXL-1020
DrugBank: CXL-1020 (DB15326)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CXL regardless of medication
Trial: 12198018
Drug: Calcium supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium supplementation (714 mg/d for 12 months)
Trial: 10200128
Drug: Single 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single 2 g/kg dose of IVGG
Trial: 10200128
Drug: Non-IVGG treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-IVGG treatment
Trial: 10200128
Drug: 400 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg/kg per day for 5 consecutive days of IVGG
Trial: 1456570
Drug: Prednisone 50
RxNorm normalized name: prednisone 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisone 50 mg at 1500 h
Trial: 1456570
Drug: Prednisone 50
RxNorm normalized name: prednisone 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisone 50 mg at 0800 h
Trial: 1456570
Drug: Prednisone 50
RxNorm normalized name: prednisone 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisone 50 mg at 2000 h
Trial: 3969541
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg metolazone
Trial: 3969541
Drug: 160 mg
RxNorm normalized name: nadolol 160 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 160 mg furosemide
Trial: 3969541
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg pindolol
Trial: 3969541
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg hydralazine
Trial: 3969541
Drug: Diuretic monotherapy
RxNorm normalized name: hydralazine hydrochloride / hydrochlorothiazide / reserpine Oral Tablet [Diuretic Ap-Es]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diuretic monotherapy (metolazone or furosemide)
Trial: 3969541
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of three different antihypertensive agents
Trial: 31114137
Drug: Probiotics (Bacillus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotics (Bacillus subtilis and Enterococcus faecium) with esomeprazole 20 mg b.i.d. for 8 weeks
Trial: 31114137
Drug: Placebo with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with esomeprazole 20 mg b.i.d. for 8 weeks
Trial: 21099198
Drug: Ethyl chloride
RxNorm normalized name: Ethyl Chloride
DrugBank: Ethyl chloride (DB13259)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethyl chloride (EC) spray
Trial: 17012873
Drug: ChimeriVax-DEN2 (high
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ChimeriVax-DEN2 (high dose, 5 log PFU)
Trial: 17012873
Drug: ChimeriVax-DEN2 (low
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ChimeriVax-DEN2 (low dose, 3 log PFU)
Trial: 17012873
Drug: ChimeriVax-DEN2 (high
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ChimeriVax-DEN2 (high dose) in YF immune subjects
Trial: 14617474
Drug: GnRHa (buserelin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GnRHa (buserelin acetate, 900 microg/day for 10-12 weeks followed by 4 weeks postoperative treatment)
Trial: 11063436
Drug: 1 L/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 L/d of paper-filtered coffee brewed with 70 g regular ground beans
Trial: 8428870
Drug: Methylphenidate in
RxNorm normalized name: Product containing methylphenidate in oral dose form (medicinal product form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylphenidate in combination with behavioral parent training plus child self-control instruction
Trial: 3619741
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg of intravenous metoclopramide hydrochloride
Trial: 27219616
Drug: Beta-blockers (Metoprolol,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-blockers (Metoprolol, 37±13.5 mg, n=48)
Trial: 27219616
Drug: No beta-blockers
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No beta-blockers (n=52)
Trial: 24593273
Drug: Long-term administration
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term administration of itraconazole (ITCZ) - 400 mg/day for 2 days followed by 200 mg/day until day +90 post transplantation.
Trial: 24593273
Drug: Short-term administration
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short-term administration of itraconazole (ITCZ) - 400 mg/day for 2 days followed by 200 mg/day until day +30 post transplantation.
Trial: 24593273
Drug: Long-term administration
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term administration of itraconazole (ITCZ) from day +30 to day +90.
Trial: 24593273
Drug: Short-term administration
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short-term administration of itraconazole (ITCZ) from day +30 to day +90.
Trial: 24593273
Drug: Long-term administration
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term administration of itraconazole (ITCZ) - drug-related adverse events.
Trial: 24593273
Drug: Short-term administration
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short-term administration of itraconazole (ITCZ) - drug-related adverse events.
Trial: 22536073
Drug: Omega-3 supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3 supplementation (2.4 g omega-3, 1800 mg eicosapentaenoic acid + 600 mg docosahexaenoic acid)
Trial: 20688775
Drug: Magnesium supplementation
RxNorm normalized name: Magnesium
DrugBank: Magnesium (DB14513)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnesium supplementation (30 mg/kg over 10 minutes in normal saline)
Trial: 20688775
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline (5 ml over 10 minutes)
Trial: 18454609
Drug: Continuous subcutaneous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous subcutaneous infusion (CSCI) of opioid for 48 hours
Trial: 18454609
Drug: Intermittent subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent subcutaneous injections (ISCI) of opioid for 48 hours
Trial: 10563072
Drug: Perindopril 4-8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perindopril 4-8 mg
Trial: 8690820
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy plus epoprostenol
Trial: 30132926
Drug: Uninterrupted NOAC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Uninterrupted NOAC therapy
Trial: 30132926
Drug: Interrupted NOAC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interrupted NOAC therapy
Trial: 22357633
Drug: Treatment order
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment order B (POWER followed by FTP)
Trial: 19071128
Drug: Metyrapone (1500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metyrapone (1500 mg)
Trial: 12493085
Drug: Low-fat, high-carbohydrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-fat, high-carbohydrate lunch (5.7 g fat)
Trial: 7639167
Drug: Complex trials
RxNorm normalized name: hesperidin complex
DrugBank: Citrus bioflavonoids (DB14586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Complex trials designed to improve reperfusion therapy